Congestive Heart Failure (2026 IMCU)

Only available as part of a package

Learning Objectives:

Upon completion, participant will be able to identify the core components of guideline-directed medical therapy (GDMT) for HFrEF and summarize the evidence-based benefits of each major drug class, including ACEi/ARB/ARNI, beta-blockers, MRAs, and SGLT2 inhibitors.
Upon completion, participant will be able to apply GDMT principles to common clinical scenarios by selecting appropriate therapies, adjusting doses, and recognizing contraindications or monitoring parameters in patients with CHF.
Upon completion, participant will be able to describe the pathophysiology, clinical presentation, and classification of congestive heart failure, including distinctions between HFrEF and HFpEF.

Arash Karnama, DO, FACOI

Clinical Associate Professor of Medicine

Oklahoma State University

Arash Karnama, DO is a clinical associate professor of medicine at Oklahoma State University Center for Health Sciences. He is a board certified interventional cardiologist. He received his Doctor of Osteopathic Medicine degree from Des Moines University. He completed his residency in internal medicine at Penn State Milton S. Hershey Medical Center. He completed his fellowship in cardiology and interventional cardiology at Oklahoma State University.

The faculty member, for this activity, has no relevant relationships with ineligible companies to disclose.